Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) has provided an announcement.
On July 11, 2025, Evaxion Biotech finalized a debt settlement agreement with the European Investment Bank (EIB), reducing its €7 million loan by €3.5 million. This was achieved by issuing warrants for 38,450,000 ordinary shares to EIB, which are exercisable immediately and expire in ten years. The agreement also included a registration rights agreement to facilitate the resale of these shares. This strategic financial move is expected to strengthen Evaxion’s financial position and enhance its operational flexibility, potentially impacting its market presence positively.
The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its significant revenue growth and positive earnings call outlook, with notable R&D achievements and partnerships. However, financial instability and negative profitability significantly weigh down the score. Technical indicators show some short-term momentum, yet valuation remains a concern due to the lack of profitability and dividends.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion Biotech is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating advanced software to develop novel immune therapies and vaccines, positioning itself at the intersection of biotechnology and artificial intelligence.
Average Trading Volume: 102,769
Technical Sentiment Signal: Sell
Current Market Cap: $3.56M
Learn more about EVAX stock on TipRanks’ Stock Analysis page.